Dmitriy Grekhnev

Dr. Dmitriy Grekhnev

orcid

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
Verified
Journal Article
Open access
PDF file
DGDmitriy Grekhnev
Dmitriy Grekhnev
EKElena Kaznacheyeva
Elena Kaznacheyeva
VVVladimir Vigont
Vladimir Vigont
The development of cell reprogramming technologies became a breakthrough in the creation of new models of human diseases, including neurodegenerative pathologies. The iPSCs-based models allow for the studying of both hereditary and sporadic cases of pathologies and produce deep insight into the molecular mechanisms underlying neurodegeneration. The use of the cells most vulnerable to a particular pathology makes it possible to identify specific pathological mechanisms and greatly facilitates the task of selecting the most effective drugs. To date, a large number of studies on patient-specific models of neurodegenerative diseases has been accumulated. In this review, we focused on the alterations of such a ubiquitous and important intracellular regulatory pathway as calcium signaling. Here, we reviewed and analyzed the data obtained from iPSCs-based models of different neurodegenerative disorders that demonstrated aberrant calcium signaling.

Verified
Journal Article
Open access
PDF file
OLOlga Lebedeva
Olga Lebedeva
ESElena Sharova
Elena Sharova
DGDmitriy Grekhnev
Dmitriy Grekhnev
LSLiubov Olegovna Skorodumova
Liubov Olegovna Skorodumova
IKIrina Kopylova
Irina Kopylova
MLMaria A. Lagarkova
Maria A. Lagarkova
About 15% of patients with parkinsonism have a hereditary form of Parkinson’s disease (PD). Studies on the early stages of PD pathogenesis are challenging due to the lack of relevant models. The most promising ones are models based on dopaminergic neurons (DAns) differentiated from induced pluripotent stem cells (iPSCs) of patients with hereditary forms of PD. This work describes a highly efficient 2D protocol for obtaining DAns from iPSCs. The protocol is rather simple, comparable in efficiency with previously published protocols, and does not require viral vectors. The resulting neurons have a similar transcriptome profile to previously published data for neurons, and have a high level of maturity marker expression. The proportion of sensitive (SOX6+) DAns in the population calculated from the level of gene expression is higher than resistant (CALB+) DAns. Electrophysiological studies of the DAns confirmed their voltage sensitivity and showed that a mutation in the PARK8 gene is associated with enhanced store-operated calcium entry. The study of high-purity DAns differentiated from the iPSCs of patients with hereditary PD using this differentiation protocol will allow for investigators to combine various research methods, from patch clamp to omics technologies, and maximize information about cell function in normal and pathological conditions.

29 November 2023 in Biochemical and Biophysical Research Communications
Verified
Journal Article
Closed access
INIuliia V. Novikova
Iuliia V. Novikova
DGDmitriy Grekhnev
Dmitriy Grekhnev
AOArina Oshkolova
Arina Oshkolova
MNMaria A. Nomerovskaya
Maria A. Nomerovskaya
DKDmitrii O. Kolesnikov
Dmitrii O. Kolesnikov
VVVladimir Vigont
Vladimir Vigont

Verified
Journal Article
Open access
PDF file
DGDmitriy Grekhnev
Dmitriy Grekhnev
AKAnna A Kruchinina
Anna A Kruchinina
VVVladimir Vigont
Vladimir Vigont
EKElena Kaznacheyeva
Elena Kaznacheyeva
Quinazoline derivatives have various pharmacological activities and are widely used in clinical practice. Here, we reviewed the proposed mechanisms of the physiological activity of the quinazoline derivative EVP4593 and perspectives for its clinical implication. We summarized the accumulated data about EVP4593 and focused on its activities in different models of Huntington’s disease (HD), including patient-specific iPSCs-based neurons. To make a deeper insight into its neuroprotective role in HD treatment, we discussed the ability of EVP4593 to modulate calcium signaling and reduce the level of the huntingtin protein. Moreover, we described possible protective effects of EVP4593 in other pathologies, such as oncology, cardiovascular diseases and parasite invasion. We hope that comprehensive analyses of the molecular mechanisms of EVP4593 activity will allow for the expansion of the scope of the EVP4593 application.

24 April 2026 in Life Science Alliance
Verified
Journal Article
Open access
PDF file
IKIrina Kopylova
Irina Kopylova
AIArtem B Ivanov
Artem B Ivanov
LELev R Eidelman
Lev R Eidelman
EZEkaterina N Zaitseva
Ekaterina N Zaitseva
EKEkaterina D Kulikova
Ekaterina D Kulikova
EOEvgenii I. Olekhnovich
Evgenii I. Olekhnovich
The clinical and genetic diversity of Parkinson’s disease (PD) makes it challenging to identify common mechanisms across different forms. To search for such shared pathways, we performed transcriptomic analysis of iPSC-derived dopaminergic neurons from patients with LRRK2 or Parkin mutations. We discovered a convergent gene expression signature in both genetic backgrounds, indicating a shift away from developmental and proliferative programs (e.g., Wnt/β-catenin signaling, cell cycle) and toward pathways of mature neuronal function (e.g., synaptic transmission, potassium channels). This shift was particularly pronounced in LRRK2 neurons, which showed enhanced markers of synaptic maturation. Concurrently, PD neurons exhibited down-regulation of gene programs supporting axon growth and structural development and upregulated TRAIL (TNF-related apoptosis-inducing ligand) apoptotic pathway. Our findings suggest that in these hereditary forms of PD, distinct mutations may propel neurons toward a similar state of premature specialization coupled with impaired structural development and increased vulnerability, revealing a potential common path in disease pathogenesis.

27 October 2026 in Genes & Diseases
Verified
Journal Article
Open access
DGDmitriy Grekhnev
Dmitriy Grekhnev
EVEgor Alexeevich Volovikov
Egor Alexeevich Volovikov
OLOlga Lebedeva
Olga Lebedeva
ASAnton Skopin
Anton Skopin
KGKonstantin Gusev
Konstantin Gusev
VVVladimir Vigont
Vladimir Vigont